[floblu14]

I'm out of COLL. Made a great profit - $500+K in 14 months.

Someone else can take the reigns.

Good luck to all.

FLO

P.S. My new investment - ENTA.

[floblu14]

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Stock analysts at HC Wainwright reduced their FY2024 earnings estimates for Collegium Pharmaceutical in a research note issued on Tuesday, July 30th. HC Wainwright analyst O. Livnat now forecasts that the specialty pharmaceutical company will earn $5.61 per share for the year, down from their previous estimate of $5.65. HC Wainwright currently has a "Buy" rating and a $47.00 price target on the stock. The consensus estimate for Collegium Pharmaceutical's current full-year earnings is $5.68 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical's Q4 2024 earnings at $1.51 EPS and FY2025 earnings at $5.85 EPS.

https://www.marketbeat.com/instant-alerts/nasdaq-coll-analyst-earnings-estimates-2024-08-01/

[floblu14]

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
July 29, 2024

– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) –

– H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year –

– Transaction Expected to be Immediately Accretive to Adjusted EBITDA –

– Acquisition Funded by Collegium’s Cash on Hand and New Five-Year Financing with Significantly Improved
Terms –

– Collegium Estimates Q2’24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms 2024
Financial Guidance for the Current Business –

– Conference Call Scheduled for Today at 8:30 a.m. ET –

STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive agreement pursuant to which Collegium will acquire Ironshore for $525 million in cash with the potential for an additional $25 million commercial milestone payment.

Ironshore is a privately held, pharmaceutical company that markets and distributes Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant prescription medicine for the treatment of attention deficit hyperactivity disorder (ADHD) in people six years of age and older and the only stimulant medication that is dosed in the evening. The acquisition of Ironshore will represent a significant milestone in advancing Collegium’s mission of building a leading, diversified specialty pharmaceutical company by expanding the Company’s business beyond pain management and establishing a commercial presence in a new and growing market.

“The Ironshore acquisition is a unique opportunity to deliver a transaction that is immediately accretive to Collegium while meeting all of our strategic objectives through the addition of a growing commercial asset that diversifies our portfolio, has significant revenue potential and exclusivity into the 2030s,” said Michael Heffernan, Chairman and Interim President and Chief Executive Officer of Collegium. “The addition of Jornay PM will establish a new presence for Collegium in ADHD, a large and growing market, where we can leverage our core commercial competencies and proven commercial execution capabilities to maximize the brand’s potential. Our healthy balance sheet and strong financial position enabled us to secure attractive financing for the transaction with terms that reduce our cost of capital and enhance our flexibility in the management of our debt.”

“We are pleased to announce this transaction with Collegium, which recognizes the value of Jornay PM and the success of Ironshore’s talented team in the delivery of an important and differentiated treatment option for patients with ADHD and their caregivers,” said Stephanie Read, Chief Executive Officer of Ironshore. “Our team has worked tirelessly to bring Jornay PM to the ADHD community and we are excited that Collegium recognizes Jornay PM’s long-term potential and is committed to supporting its continued growth.”

Transaction Rationale

Strategically aligns with Collegium’s mission of building a leading, diversified specialty pharmaceutical company by broadening the commercial portfolio beyond pain management and establishing a commercial presence in neurology via the large and growing ADHD market.
Jornay PM is poised to become Collegium’s leading growth driver. Net revenue for Jornay PM is expected to be in excess of $100 million in 2024. In the first half of 2024, Jornay PM prescriptions grew 32% year-over-year. For the full-year 2023, the product generated approximately 490,000 prescriptions, a 58% increase compared to 2022. Jornay PM is a highly differentiated treatment for ADHD due to its evening dosing, smooth therapeutic effect and dose-dependent duration.
Jornay PM is supported by 16 Orange Book-listed patents, with expiries in 2032.
Further strengthens Collegium’s financial position through an increased revenue base, expected immediate accretion to adjusted EBITDA and accelerated cash flow generation.
Additional Transaction Details

Under the terms of the agreement, Collegium will acquire all the outstanding shares of Ironshore for $525 million in cash at closing. Collegium will also pay Ironshore shareholders $25 million in additional consideration if Jornay PM net revenue exceeds a defined threshold in 2025.
The all-cash consideration will be funded by a combination of Collegium’s existing cash on hand and a $646 million secured financing from funds managed by Pharmakon Advisors, LP (Pharmakon). The new five-year term loan will replace the existing Collegium term loan from Pharmakon and reduce the interest rate by 300 basis points.
At year-end 2024, Collegium expects net leverage to be less than two times based on estimated 2024 pro forma combined adjusted EBITDA.
Collegium expects this transaction to be immediately accretive to adjusted EBITDA, excluding transaction costs.
Timing to Close

The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close in the third quarter of 2024, subject to customary closing conditions, including receipt of required regulatory approvals.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-acquire-ironshore-therapeutics-expanding-neurology

[floblu14]

Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024

July 25, 2024

STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2024 financial results after the market closes on Thursday, August 8, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-report-second-quarter-2024-financial-results-august-8

[floblu14]

Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
June 13, 2024

STOUGHTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June 27, 2025, to July 3, 2026. FDA’s grant of pediatric exclusivity now extends exclusivity of the Nucynta Franchise an additional six months, to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER.

“We are pleased with FDA’s grant of pediatric exclusivity for the Nucynta Franchise,” said Thomas Smith, M.D., Collegium’s Chief Medical Officer. “This grant of pediatric exclusivity enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of people living with serious medical conditions and the communities we serve.”

Nucynta is currently approved in the U.S. for the management of acute pain severe enough to require an opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative treatments are inadequate in adults and pediatric patients aged six years and older with a body weight of at least 40 kg.

Nucynta ER is currently approved in the U.S. for the management of severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative treatment options are inadequate, and severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-obtains-six-month-extension-us-pediatric-exclusivity

[floblu14]

Management has already stated such. However, it's still positive to see the following in print -

The company has now completed a majority of its multi-year payer contracts at significantly higher margins to COLL. To underscore this development and what the market is missing, if COLL were to run its business as-is and retire its debt, we estimate it could have a $1 billion net cash position by 2027. Furthermore, if their largest potential competitor (Teva Pharmaceuticals) stays out of the market, it could produce another $1 billion of free cash flow over the next three years. The current market capitalization is roughly $1 billion…”

https://finance.yahoo.com/news/collegium-pharmaceutical-inc-nasdaq-coll-211603220.html

[floblu14]

Jefferies upgrades Collegium to buy, cites upside related to LOEs -

Jun. 07, 2024 12:13 PM ET

Jefferies upgraded Collegium (NASDAQ:COLL) to buy, stating it believes the upside potential related to upcoming losses of market exclusivity for Collegium's drugs Nucynta and Belbuca is underappreciated.

The investment bank said it sees several drivers for the drugs despite the LOEs, including a Nucynta partnership with Hikma, pediatric extensions for Nucynta, and uncertainty about Teva's launch of a generic version of Belbuca. It also believes 2024 EBITDA consensus is “too low.”

Jeffries also noted that the company’s cash generation was “significant,” with its net cash expected to eclipse its market cap in fiscal 2028. It added that the company “could likely take itself private in the 2028 timeframe.”

Jefferies set its price target for the stock at $44.

https://seekingalpha.com/news/4114181-jefferies-upgrades-collegium-to-buy-cites-upside-related-to-loes?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain

[floblu14]

JEFFERIES raises COLL to a BUY from HOLD with a price target - $44.

[floblu14]

Since Joe Ciaffoni was terminated, he has been selling his large holdings piecemeal. As a result, the share price is going SOUTH. Obviously, he wants to get revenge & sink the shareholders.

Resolution - B.O.D. - don't vest the upcoming, new President et al with as many perks!!

Another quick move by the B.O.D. - use some of $115M (left out of $150M) to purchase J.C's COLL securities.

[floblu14]

Collegium to Participate in Jefferies Global Healthcare Conference
May 29, 2024

STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY from June 5-6, 2024.

Details of the event are as follows:
Fireside Chat Date and Time: Wednesday, June 5, 2024, at 9:30 a.m. ET

The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-participate-jefferies-global-healthcare-conference

[floblu14]

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call Transcript
Published on May 14, 2024

https://www.insidermonkey.com/blog/collegium-pharmaceutical-inc-nasdaqcoll-q1-2024-earnings-call-transcript-1303222/

[floblu14]

Collegium Announces $35 Million Accelerated Share Repurchase Program
May 13, 2024

STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $115 million remaining under the program.

“Our financial and strategic execution bolster the strength of our business today and in the future. Collegium’s strong start to 2024 was supported by robust cash generation, momentum in Belbuca® prescriptions, improved Xtampza® ER gross-to-net and the Nucynta Franchise authorized generic agreement, all of which put us on track to meet our 2024 financial guidance and improve our outlook in 2025 and beyond,” said Colleen Tupper, Chief Financial Officer of Collegium. “This $35 million ASR program reinforces our belief that the value of Collegium is underappreciated. We remain committed to leveraging our $150 million share repurchase program, which is authorized through the second quarter of 2025, to create value for our shareholders through our capital deployment strategy.”

Under terms of the agreement, Collegium will pay $35 million to Jefferies LLC and will receive an initial delivery of 888,889 shares, based on the $31.50 closing stock price of Collegium’s common stock on May 10, 2024, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium’s common stock during the term of the ASR and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the third quarter of 2024. As of March 31, 2024, Collegium had approximately 32.7 million shares outstanding.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-35-million-accelerated-share-repurchase

[floblu14]

FWIW - 5/10
Before the 6 point drop -
We believe that there continues to be a disconnect between the intrinsic value of the company and our share price, which enables us to continue to opportunistically return value to our shareholders by leveraging our share repurchase program. Colleen Tupper - 1stQ CC

https://za.investing.com/news/earnings-call-collegium-pharmaceutical-projects-robust-growth-in-2024-93CH-3141800

[floblu14]

In-fighting, disagreements, personality clashes - totally not predicted - who knows??

Joe has my vote.

Need Comments.

Collegium Announces CEO Transition

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-ceo-transition

[floblu14]

INVESTOR PRESENTATION SLIDES -

https://ir.collegiumpharma.com/static-files/256cf28c-c774-44b0-82b5-e46427a28463

[floblu14]

Excellent -

Collegium Reports First Quarter 2024 Financial Results

May 9, 2024

– Generated Q1’24 Net Revenue of $144.9 Million –

– Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year –

– Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million –

– Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year –

– Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program –

– Reaffirmed Full-Year 2024 Guidance –

Joe C. to step down as President & C.E.O. -

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-first-quarter-2024-financial-results

[floblu14]

Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER

April 29, 2024

STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta® ER (“the Nucynta Franchise”) in the United States.

“Our agreement with Hikma bolsters the value of the Nucynta Franchise through 2025 and beyond,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Collegium is pleased to work with Hikma, an industry leader, to ensure that these important products continue to be manufactured to the highest quality standards and remain broadly and consistently accessible to appropriate patients.”

Under the terms of the agreement:

Collegium will manufacture and supply Hikma with all authorized generic product for sale on an exclusive basis during the term of the agreement.
Hikma will sell the authorized generic forms of the Nucynta Franchise in the United States, commencing 30 days prior to the anticipated loss of exclusivity for each product, or earlier under certain circumstances.

Collegium will receive a meaningful share of net profits of the authorized generic products, that declines based on the number of generic entrants, if any. [NO TEVA, HOPEFULLY.]

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-authorized-generic-agreement-hikma

[floblu14]

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 - APRIL 11

......announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2; ISIN No. US19459JAA25) for redemption on Friday, June 14, 2024 (the “Redemption Date”).

Read more:
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-pharmaceutical-inc-announces-redemption-outstanding

[floblu14]

Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference - Wed, April 3, 2024 at 8:00 AM EDT

STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference being held virtually from April 8-11, 2024.

Details of the event are as follows:
Fireside Chat Date and Time: Wednesday, April 10, 2024, at 3:45 p.m. ET

https://finance.yahoo.com/news/collegium-participate-23rd-annual-needham-120000163.html

[floblu14]

3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock
Zacks Equity Research
Wed, March 13, 2024

EXCERPTS:
Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors

The company's EPS is expected to grow 15% this year, crushing the industry average, which calls for EPS growth of 14.7%.

Right now, year-over-year cash flow growth for Collegium Pharmaceutical is 27.9%, which is higher than many of its peers. In fact, the rate compares to the industry average of 2.4%.

There have been upward revisions in current-year earnings estimates for Collegium Pharmaceutical. The Zacks Consensus Estimate for the current year has surged 5.2% over the past month.

Bottom Line

While the overall earnings estimate revisions have made Collegium Pharmaceutical a Zacks Rank #1 stock, it has earned itself a Growth Score of A ....

READ MORE:
https://finance.yahoo.com/news/3-reasons-why-collegium-pharmaceutical-164505922.html

[floblu14]

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Charles Schwab Investment Management Inc.
Mar 3rd, 2024

Charles Schwab Investment Management Inc. raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 5.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 310,139 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,667 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Collegium Pharmaceutical were worth $6,932,000 at the end of the most recent quarter.

https://www.defenseworld.net/2024/03/03/collegium-pharmaceutical-inc-nasdaqcoll-shares-bought-by-charles-schwab-investment-management-inc.html

[floblu14]

Are You Looking for a Top Momentum Pick? Why Collegium Pharmaceutical (COLL) is a Great Choice
March 01, 2024 — 12:00 pm EST

For COLL, shares are up 11.57% over the past week while the Zacks Medical - Drugs industry is down 0.48% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 9.68% compares favorably with the industry's 1.54% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Collegium Pharmaceutical have risen 35.06%, and are up 34.86% in the last year. In comparison, the S&P 500 has only moved 11.77% and 30%, respectively.

Investors should also pay attention to COLL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. COLL is currently averaging 407,425 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with COLL.

Over the past two months, 4 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost COLL's consensus estimate, increasing from $6.02 to $6.29 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been no downward revisions in the same time period.

Read more:
https://www.nasdaq.com/articles/are-you-looking-for-a-top-momentum-pick-why-collegium-pharmaceutical-coll-is-a-great

[floblu14]

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective increased by analysts at Truist Financial from $37.00 to $40.00 in a note issued to investors on Monday. The firm currently has a "buy" rating on the specialty pharmaceutical company's stock. Truist Financial's price objective points to a potential upside of 10.04% from the company's previous close.

[FLO's price objective -$64 ]

BTW - None of these brokerage houses have taken in account a possible acquisition. Last time that was announced (BDSI) COLL surged $3+ that one day!

[floblu14]

Collegium Pharmaceutical Q4: The Beat Goes On

Excerpts:

The company has been paying down debt and repurchasing stock with its impressive operational cash flow.

The shares have gathered momentum since we last gave a "thumbs up" to this name in late October. We take a look at earnings results and update our analysis around this solid small cap

Collegium posted its fourth quarter numbers on February 22nd. The company delivered non-GAAP earnings of $1.58 a share, more than 30 cents a share above estimates. Revenues rose 15.5% on a year-over-year to $149.7 million, slightly above the consensus. For the year, net product revenues came in at $566.8 million, up 22% over FY2022. Belbuca revenue was a core contributor to growth as net product revenues rose 17% to $49.3 million in the quarter. Xtampza ER did even better with a 38% rise from 4Q2022 to $48.5 million.

Since fourth quarter results hit the wires, both Needham ($40 price target) and Piper Sandler ($39 price target) have reiterated Buy ratings on the stock. H.C. Wainwright maintained its Hold rating on the shares.

Verdict:
Collegium Pharmaceutical made $1.29 a share in FY2023 on just under $567 million in sales. The current analyst firm consensus has profits jumping to $3.97 a share in FY2024 and $6.15 a share in FY2025 on slight increases in revenues. It should be noted these estimates are from just three analyst firms and vary widely for both FY2024 ($2.76 to $6.18 a share) and FY2025 ($3.60 to $8.11 a share).

Even at the low end of estimates, earnings look set to increase at a rapid rate over the next two years. The stock sells at just over 9 times the consensus EPS estimate for this fiscal year. The shares trading near the conversion price of Collegium's convertible debt could be a bit of an overhang.

Read more:
https://seekingalpha.com/article/4673487-collegium-pharmaceutical-q4-the-beat-goes-on

[floblu14]

New Career Post -

Senior Supply Chain Planner

RESPONSIBILITIES
[Excerpt]
Proactively and independently manage production schedule, inventory levels, and shipment tracker to ensure materials are ordered, received, tested, and released in a timely fashion to support the integrated business plan

Compensation $102,000—$111,000 USD

Read more:
https://boards.greenhouse.io/collegiumpharma/jobs/4339159006

[floblu14]

New Career Posting:

Senior Manager, Market Access Operations

Pay Range
$206,000—$213,000 USD

https://boards.greenhouse.io/collegiumpharma/jobs/4339168006

[floblu14]

COLL Earnings Call Transcript:
https://seekingalpha.com/article/4672760-collegium-pharmaceuticals-coll-q4-2023-earnings-call-transcript

COLL Power Point Slide Presentation:
https://ir.collegiumpharma.com/static-files/c4fd20ae-6fec-47fa-b9c0-ba52bc8911e3

[floblu14]

On February 22, 2024, Collegium Pharmaceutical Inc (NASDAQ:COLL) released its 8-K filing, announcing record financial results for the fourth quarter and the full year ended December 31, 2023. The specialty pharmaceutical company, known for its abuse-deterrent products and patented DETERx platform technology, reported significant growth in revenue and earnings, surpassing its operational objectives and enhancing shareholder value.

Collegium Pharmaceutical Inc's President and CEO, Joe Ciaffoni, expressed satisfaction with the company's performance, stating,

2023 was a banner year for Collegium Pharmaceutical. We delivered record financial results, achieved our operational objectives and delivered value to shareholders through our share repurchase program."

The company's focus for 2024 is on operational execution, aiming to meet financial guidance and create shareholder value.

Colleen Tupper, Chief Financial Officer, highlighted the company's financial achievements, including record revenue, adjusted EBITDA, and free cash flow. She emphasized the strategic financial management that led to a stronger balance sheet and capital return to shareholders. Tupper anticipates continued growth in 2024, driven by product sales and cost structure leverage.

Financial Performance Analysis
Collegium Pharmaceutical Inc's financial results reflect a robust performance in a competitive industry. The company's record net revenue of $149.7 million for the fourth quarter and $566.8 million for the full year signifies a strong market demand for its products, particularly Belbuca and Xtampza ER. The GAAP net income figures of $31.9 million for the quarter and $48.2 million for the year demonstrate effective cost management and operational efficiency.

The adjusted EBITDA of $104.2 million for the quarter and $367.0 million for the year is a critical metric for investors, as it illustrates the company's profitability and ability to generate cash from operations. The substantial reduction in debt and the successful refinancing of convertible debt are indicative of prudent financial stewardship, which is essential for sustaining growth and weathering market volatility.

Collegium Pharmaceutical Inc's commitment to shareholder returns, as evidenced by the $75.0 million share repurchase, is a testament to the company's confidence in its financial health and long-term prospects. The projected financial guidance for 2024, with net revenue expected to be between $580.0 to $595.0 million and adjusted EBITDA between $380.0 to $395.0 million, sets an optimistic tone for the company's future performance.

In conclusion, Collegium Pharmaceutical Inc's record earnings for the fourth quarter and full year of 2023 reflect a company that is not only thriving in its market niche but is also strategically positioned for continued growth. The company's financial discipline and commitment to shareholder value are likely to appeal to value investors....

Read more:
https://finance.yahoo.com/news/heres-key-metrics-tell-us-000009621.html

CC: Coleen Tupper - Our stock is undervalued. ....Repurchase program of an additional $150M in the next 18 months.

[floblu14]

COLL - ESG REPORT for 2023

https://www.collegiumpharma.com/wp-content/uploads/Collegium-Pharmaceutical_2023-ESG-Report.pdf

[floblu14]

New Career Posting other than Sales -

Senior Manager, Total Rewards & HR Operations

https://boards.greenhouse.io/collegiumpharma/jobs/4336527006

1st time salary is stated - competition must be doing such -
$159,837—$176,600 USD

[floblu14]

COLL might possibly beat earnings estimate this past Q - nice!

BTW - check out ENTA - bought a large interest recently - upcoming trial results & suit against PFIZER
https://www.enanta.com/

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-files-patent-infringement-suit-against

[floblu14]

FORM SC 13 G/A - this A.M. -

Rubric Capital Management LP reports ownership of 2,758,253 shares of Common Stock & 8.46% of COLL common shares.

https://ir.collegiumpharma.com/static-files/d9ec241d-bf09-43b2-add2-0fcba66b8818

[floblu14]

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
February 8, 2024

STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-report-fourth-quarter-and-full-year-2023-financial

[floblu14]

Collegium Pharmaceutical (NASDAQ:COLL) Given “Buy” Rating at Needham & Company LLC
Posted by Defense World Staff on Feb 3rd, 2024

Needham & Company LLC reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a report released on Friday morning, Benzinga reports. They currently have a $40.00 target price on the specialty pharmaceutical company’s stock.

https://www.defenseworld.net/2024/02/03/collegium-pharmaceutical-nasdaqcoll-given-buy-rating-at-needham-company-llc.html